vs
Enact Holdings, Inc.（ACT）与PHIBRO ANIMAL HEALTH CORP（PAHC）财务数据对比。点击上方公司名可切换其他公司
PHIBRO ANIMAL HEALTH CORP的季度营收约是Enact Holdings, Inc.的1.2倍（$373.9M vs $312.7M），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 3.6%），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 3.6%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
ACT vs PAHC — 直观对比
营收规模更大
PAHC
是对方的1.2倍
$312.7M
营收增速更快
PAHC
高出17.3%
3.6%
两年增速更快
PAHC
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $312.7M | $373.9M |
| 净利润 | — | $27.5M |
| 毛利率 | — | 35.5% |
| 营业利润率 | 71.3% | 13.5% |
| 净利率 | — | 7.3% |
| 营收同比 | 3.6% | 20.9% |
| 净利润同比 | — | 762.1% |
| 每股收益（稀释后） | $1.23 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTPAHC
| Q4 25 | $312.7M | $373.9M | ||
| Q3 25 | $311.5M | $363.9M | ||
| Q2 25 | $304.9M | $378.7M | ||
| Q1 25 | $306.8M | $347.8M | ||
| Q4 24 | $301.8M | $309.3M | ||
| Q3 24 | $309.6M | $260.4M | ||
| Q2 24 | $298.8M | $273.2M | ||
| Q1 24 | $291.6M | $263.2M |
净利润ACTPAHC
| Q4 25 | — | $27.5M | ||
| Q3 25 | — | $26.5M | ||
| Q2 25 | — | $17.2M | ||
| Q1 25 | — | $20.9M | ||
| Q4 24 | — | $3.2M | ||
| Q3 24 | — | $7.0M | ||
| Q2 24 | — | $752.0K | ||
| Q1 24 | — | $8.4M |
毛利率ACTPAHC
| Q4 25 | — | 35.5% | ||
| Q3 25 | — | 32.9% | ||
| Q2 25 | — | 29.0% | ||
| Q1 25 | — | 30.1% | ||
| Q4 24 | — | 32.9% | ||
| Q3 24 | — | 32.1% | ||
| Q2 24 | — | 31.9% | ||
| Q1 24 | — | 30.2% |
营业利润率ACTPAHC
| Q4 25 | 71.3% | 13.5% | ||
| Q3 25 | 67.4% | 14.1% | ||
| Q2 25 | 70.4% | 8.9% | ||
| Q1 25 | 68.9% | 9.6% | ||
| Q4 24 | 68.9% | 8.3% | ||
| Q3 24 | 74.1% | 6.8% | ||
| Q2 24 | 78.6% | 6.7% | ||
| Q1 24 | 70.6% | 7.6% |
净利率ACTPAHC
| Q4 25 | — | 7.3% | ||
| Q3 25 | — | 7.3% | ||
| Q2 25 | — | 4.5% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 3.2% |
每股收益（稀释后）ACTPAHC
| Q4 25 | $1.23 | $0.67 | ||
| Q3 25 | $1.10 | $0.65 | ||
| Q2 25 | $1.11 | $0.43 | ||
| Q1 25 | $1.08 | $0.51 | ||
| Q4 24 | $1.05 | $0.08 | ||
| Q3 24 | $1.15 | $0.17 | ||
| Q2 24 | $1.16 | $0.02 | ||
| Q1 24 | $1.01 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $582.5M | $74.5M |
| 总债务越低越好 | $744.5M | $624.2M |
| 股东权益账面价值 | $5.4B | $332.4M |
| 总资产 | $6.9B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.14× | 1.88× |
8季度趋势，按日历期对齐
现金及短期投资ACTPAHC
| Q4 25 | $582.5M | $74.5M | ||
| Q3 25 | $545.6M | $85.3M | ||
| Q2 25 | $616.0M | $77.0M | ||
| Q1 25 | $639.0M | $70.4M | ||
| Q4 24 | $602.8M | $67.1M | ||
| Q3 24 | $674.9M | $89.8M | ||
| Q2 24 | $711.3M | $114.6M | ||
| Q1 24 | $624.3M | $98.7M |
总债务ACTPAHC
| Q4 25 | $744.5M | $624.2M | ||
| Q3 25 | $744.1M | $628.0M | ||
| Q2 25 | $743.8M | $631.7M | ||
| Q1 25 | $743.4M | $635.4M | ||
| Q4 24 | $743.0M | $639.1M | ||
| Q3 24 | $742.7M | $295.2M | ||
| Q2 24 | $742.4M | $312.1M | ||
| Q1 24 | $746.1M | — |
股东权益ACTPAHC
| Q4 25 | $5.4B | $332.4M | ||
| Q3 25 | $5.3B | $311.7M | ||
| Q2 25 | $5.2B | $285.7M | ||
| Q1 25 | $5.1B | $266.0M | ||
| Q4 24 | $5.0B | $246.8M | ||
| Q3 24 | $5.0B | $258.5M | ||
| Q2 24 | $4.8B | $256.6M | ||
| Q1 24 | $4.7B | $270.1M |
总资产ACTPAHC
| Q4 25 | $6.9B | $1.4B | ||
| Q3 25 | $6.9B | $1.4B | ||
| Q2 25 | $6.8B | $1.4B | ||
| Q1 25 | $6.7B | $1.3B | ||
| Q4 24 | $6.5B | $1.3B | ||
| Q3 24 | $6.6B | $966.3M | ||
| Q2 24 | $6.3B | $982.2M | ||
| Q1 24 | $6.3B | $979.0M |
负债/权益比ACTPAHC
| Q4 25 | 0.14× | 1.88× | ||
| Q3 25 | 0.14× | 2.01× | ||
| Q2 25 | 0.14× | 2.21× | ||
| Q1 25 | 0.15× | 2.39× | ||
| Q4 24 | 0.15× | 2.59× | ||
| Q3 24 | 0.15× | 1.14× | ||
| Q2 24 | 0.15× | 1.22× | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $724.5M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | — | $8.3M |
| 自由现金流率自由现金流/营收 | — | 2.2% |
| 资本支出强度资本支出/营收 | — | 3.0% |
| 现金转化率经营现金流/净利润 | — | 0.70× |
| 过去12个月自由现金流最近4个季度 | — | $47.3M |
8季度趋势，按日历期对齐
经营现金流ACTPAHC
| Q4 25 | $724.5M | $19.4M | ||
| Q3 25 | $192.0M | $9.3M | ||
| Q2 25 | $119.5M | $21.3M | ||
| Q1 25 | $226.7M | $43.2M | ||
| Q4 24 | $686.3M | $3.1M | ||
| Q3 24 | $188.1M | $12.6M | ||
| Q2 24 | $144.7M | $28.4M | ||
| Q1 24 | $187.3M | $11.4M |
自由现金流ACTPAHC
| Q4 25 | — | $8.3M | ||
| Q3 25 | — | $-4.5M | ||
| Q2 25 | — | $8.1M | ||
| Q1 25 | — | $35.4M | ||
| Q4 24 | — | $-4.7M | ||
| Q3 24 | — | $3.0M | ||
| Q2 24 | — | $15.4M | ||
| Q1 24 | — | $1.7M |
自由现金流率ACTPAHC
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | -1.2% | ||
| Q2 25 | — | 2.1% | ||
| Q1 25 | — | 10.2% | ||
| Q4 24 | — | -1.5% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 5.6% | ||
| Q1 24 | — | 0.6% |
资本支出强度ACTPAHC
| Q4 25 | — | 3.0% | ||
| Q3 25 | — | 3.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 4.8% | ||
| Q1 24 | — | 3.7% |
现金转化率ACTPAHC
| Q4 25 | — | 0.70× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 2.07× | ||
| Q4 24 | — | 0.97× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 37.80× | ||
| Q1 24 | — | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACT
暂无分部数据
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
